onr:"swepub:oai:prod.swepub.kib.ki.se:135013424"
Search: onr:"swepub:oai:prod.swepub.kib.ki.se:135013424" > Risk of invasive me...
- 1 of 1
- Previous record
- Next record
- To hitlist
- Mercer, LK (author)
Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers
- Article/chapterEnglish2017
Publisher, publication year, extent ...
- 2016-06-15
- BMJ,2017
Numbers
- LIBRIS-ID:oai:prod.swepub.kib.ki.se:135013424
- http://kipublications.ki.se/Default.aspx?queryparsed=id:135013424URI
- https://doi.org/10.1136/annrheumdis-2016-209285DOI
Supplementary language notes
- Language:English
- Summary in:English
Part of subdatabase
- SwePubSwePub
Classification
Notes
- Some studies have reported a possible association between exposure to tumour necrosis factor (TNF) inhibitors and an increased risk of melanoma. The aim of this study was to investigate the incidence of invasive cutaneous melanomas in patients with rheumatoid arthritis (RA) treated with TNF inhibitors (TNFi), other biologic disease modifying drugs and non-biologic therapy.MethodsEleven biologic registers from nine European countries participated in this collaborative project. According to predefined exposure definitions, cohorts of patients with RA were selected. Using the country-specific general population of each register as reference, age, sex and calendar year standardised incidence ratios (SIRs) of invasive histology-confirmed cutaneous melanoma were calculated within each register. Pooled SIR and incidence rate ratios (IRRs) comparing biologic cohorts to biologic-naïve were calculated across countries by taking the size of the register into account.ResultsOverall 130 315 RA patients with a mean age of 58 years contributing 579 983 person-years were available for the analysis and 287 developed a first melanoma. Pooled SIRs for biologic-naïve, TNFi and rituximab-exposed patients were 1.1 (95% CI 0.9 to 1.4), 1.2 (0.99 to 1.6) and 1.3 (0.6 to 2.6), respectively. Incidence rates in tocilizumab and abatacept-exposed patients were also not significantly increased. IRR versus biologic-naïve patients were: TNFi 1.1 (95% CI 0.8 to 1.6); rituximab 1.2 (0.5 to 2.9).ConclusionsThis large European collaborative project did not confirm an overall increased risk of melanoma following exposure to TNFi.
Added entries (persons, corporate bodies, meetings, titles ...)
- Askling, JKarolinska Institutet (author)
- Raaschou, PKarolinska Institutet (author)
- Dixon, WG (author)
- Dreyer, L (author)
- Hetland, ML (author)
- Strangfeld, A (author)
- Zink, A (author)
- Mariette, X (author)
- Finckh, A (author)
- Canhao, H (author)
- Lannone, F (author)
- Zavada, J (author)
- Morel, J (author)
- Gottenberg, JE (author)
- Hyrich, KL (author)
- Listing, J (author)
- Karolinska Institutet (creator_code:org_t)
Related titles
- In:Annals of the rheumatic diseases: BMJ76:2, s. 386-3911468-20600003-4967
Internet link
Find in a library
- Annals of the rheumatic diseases (Search for host publication in LIBRIS)
To the university's database
- 1 of 1
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Mercer, LK
- Askling, J
- Raaschou, P
- Dixon, WG
- Dreyer, L
- Hetland, ML
- show more...
- Strangfeld, A
- Zink, A
- Mariette, X
- Finckh, A
- Canhao, H
- Lannone, F
- Zavada, J
- Morel, J
- Gottenberg, JE
- Hyrich, KL
- Listing, J
- show less...
- Articles in the publication
- Annals of the rh ...
- By the university
- Karolinska Institutet
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
